346 related articles for article (PubMed ID: 15210071)
1. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.
Ma XH; Zhang XY; Tan JJ; Chen WZ; Wang CX
Acta Pharmacol Sin; 2004 Jul; 25(7):950-8. PubMed ID: 15210071
[TBL] [Abstract][Full Text] [Related]
2. Application of CoMFA and CoMSIA 3D-QSAR and docking studies in optimization of mercaptobenzenesulfonamides as HIV-1 integrase inhibitors.
Kuo CL; Assefa H; Kamath S; Brzozowski Z; Slawinski J; Saczewski F; Buolamwini JK; Neamati N
J Med Chem; 2004 Jan; 47(2):385-99. PubMed ID: 14711310
[TBL] [Abstract][Full Text] [Related]
3. Exploring molecular shape analysis of styrylquinoline derivatives as HIV-1 integrase inhibitors.
Leonard JT; Roy K
Eur J Med Chem; 2008 Jan; 43(1):81-92. PubMed ID: 17452064
[TBL] [Abstract][Full Text] [Related]
4. CoMFA and CoMSIA 3D-QSAR studies on quionolone caroxylic acid derivatives inhibitors of HIV-1 integrase.
Lu P; Wei X; Zhang R
Eur J Med Chem; 2010 Aug; 45(8):3413-9. PubMed ID: 20488589
[TBL] [Abstract][Full Text] [Related]
5. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
Hou T; Zhu L; Chen L; Xu X
J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
[TBL] [Abstract][Full Text] [Related]
6. Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.
Yuan H; Parrill A
J Mol Graph Model; 2005 Jan; 23(4):317-28. PubMed ID: 15670952
[TBL] [Abstract][Full Text] [Related]
7. Docking-based 3D-QSAR study of HIV-1 integrase inhibitors.
Gupta P; Roy N; Garg P
Eur J Med Chem; 2009 Nov; 44(11):4276-87. PubMed ID: 19647906
[TBL] [Abstract][Full Text] [Related]
8. 3D-QSAR studies of quinoline ring derivatives as HIV-1 integrase inhibitors.
Sun XH; Guan JQ; Tan JJ; Liu C; Wang CX
SAR QSAR Environ Res; 2012 Oct; 23(7-8):683-703. PubMed ID: 22991976
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
[TBL] [Abstract][Full Text] [Related]
10. Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
Neamati N; Hong H; Owen JM; Sunder S; Winslow HE; Christensen JL; Zhao H; Burke TR; Milne GW; Pommier Y
J Med Chem; 1998 Aug; 41(17):3202-9. PubMed ID: 9703465
[TBL] [Abstract][Full Text] [Related]
11. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors.
Deng J; Lee KW; Sanchez T; Cui M; Neamati N; Briggs JM
J Med Chem; 2005 Mar; 48(5):1496-505. PubMed ID: 15743192
[TBL] [Abstract][Full Text] [Related]
12. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
13. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
14. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors.
Barreca ML; Ferro S; Rao A; De Luca L; Zappalà M; Monforte AM; Debyser Z; Witvrouw M; Chimirri A
J Med Chem; 2005 Nov; 48(22):7084-8. PubMed ID: 16250669
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel HIV-1 integrase inhibitors using shape-based screening, QSAR, and docking approach.
Gupta P; Garg P; Roy N
Chem Biol Drug Des; 2012 May; 79(5):835-49. PubMed ID: 22233531
[TBL] [Abstract][Full Text] [Related]
16. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
17. Rational design of novel diketoacid-containing ferrocene inhibitors of HIV-1 integrase.
da Silva CH; Del Ponte G; Neto AF; Taft CA
Bioorg Chem; 2005 Aug; 33(4):274-84. PubMed ID: 16023487
[TBL] [Abstract][Full Text] [Related]
18. 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Opera TI; Waller CL; Marshall GR
Drug Des Discov; 1994 Jul; 12(1):29-51. PubMed ID: 7578806
[TBL] [Abstract][Full Text] [Related]
19. Docking-based CoMFA and CoMSIA study of azaindole carboxylic acid derivatives as promising HIV-1 integrase inhibitors.
Yu S; Wang P; Li Y; Liu Y; Zhao G
SAR QSAR Environ Res; 2013 Oct; 24(10):819-39. PubMed ID: 23988186
[TBL] [Abstract][Full Text] [Related]
20. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors.
Majerz-Maniecka K; Musiol R; Skórska-Stania A; Tabak D; Mazur P; Oleksyn BJ; Polanski J
Bioorg Med Chem; 2011 Mar; 19(5):1606-12. PubMed ID: 21316973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]